Stockscreener 앱 받기
1.68
0.00%
0.00
Biocardia Inc 주식(BCDA)의 최신 뉴스
BioCardia outlines regulatory milestones and targets FDA and PMDA submissions for CardiAMP and Helix in Q4 2025 - MSN
Real time breakdown of BioCardia Inc. stock performanceFree Fast Gaining Stock Screener Report - Newser
BioCardia sets Q4 2025 for FDA and PMDA submissions for CardiAMP and Helix trials. - AInvest
BioCardia Advances Clinical Trials Amid Financial Challenges - TipRanks
How BioCardia Inc. stock performs during market volatility5-Year Price Trend Summary and Analysis - Newser
BioCardia (BCDA) Advances with Promising Trial Results and Strat - GuruFocus
BioCardia's (BCDA) Q2 2025 Earnings and Strategic Pivots in Cardiac Regeneration: A Deep Dive into Long-Term Investment Potential - AInvest
BioCardia's 2025 Q2 Earnings Call: Navigating Contradictions in CardiAMP's Regulatory Journey - AInvest
Earnings call transcript: BioCardia Q2 2025 reveals increased R&D expenses By Investing.com - Investing.com Nigeria
Earnings call transcript: BioCardia Q2 2025 reveals increased R&D expenses - Investing.com
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results - The Manila Times
BioCardia Narrows Loss in Fiscal Q2 - The Globe and Mail
BioCardia, Inc. SEC 10-Q Report - TradingView
BioCardia's CardiAMP Cell Therapy Achieves Key Endpoints in Phase 3 Heart Failure Trial, FDA Meeting Ahead - Stock Titan
Full technical analysis of BioCardia Inc. stockFree Verified Signal From Chart Patterns - Newser
Is BioCardia Inc. meeting your algorithmic filter criteriaPredictive Screener for Daily Trade Watch - Newser
Can momentum traders help lift BioCardia Inc.Chart Confirmation Setup with ROI Signals - Newser
Should you wait for a breakout in BioCardia Inc.Capital Safe Picks with Consistent Gains - Newser
Is BioCardia Inc. forming a reversal patternFundamental + Technical Combined Watchlist - Newser
Real time social sentiment graph for BioCardia Inc.AI Pattern Recognition and Trade Prediction - Newser
Is BioCardia Inc. still worth holding after the dipEntry Opportunity Screener with Confirmation - Newser
What institutional flow reveals about BioCardia Inc.Free Chart Alert System With Entry Targets - Newser
Can BioCardia Inc. recover in the next quarterMarket Sentiment Tracker with Smart Alerts - Newser
BioCardia Inc.’s volatility index tracking explainedVolume Spike Detection for Early Breakouts - Newser
Using data tools to time your BioCardia Inc. exitMomentum-Based Prediction for Quick Returns - Newser
Has BioCardia Inc. formed a bullish divergenceFree News Based Entry Opportunity Alerts - Newser
What candlestick patterns are forming on BioCardia Inc.Day Trading Setup Forecast with Trend Model - Newser
Biocardia BCDA 2025Q2 Earnings Preview Upside Ahead on Strategic Product Developments - AInvest
BioCardia to Host Q2 2025 Earnings Call on August 11 - AInvest
BioCardia Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - GlobeNewswire
Earnings Preview: BioCardia to Report Financial Results Post-market on August 11 - 富途牛牛
BioCardia Announces Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - AInvest
Cellular Therapeutics Pioneer BioCardia Announces Q2 2025 Earnings and Pipeline Update - Stock Titan
TR | OpenAI4o Initiates BioCardia(BCDA.US) With Hold Rating, Announces Target Price $2 - 富途牛牛
What recovery options are there for BioCardia Inc.Weekly High Conviction Trade Setup Analysis - Newser
Will breakout in BioCardia Inc. lead to full recoveryVolatility Analysis and Entry Risk Mapping - Newser
BioCardia Reveals Plans to Request Meeting With FDA Regarding CardiAMP Heart Failure Cell Therapy - CGTLive®
BioCardia Seeks FDA Approval for CardiAMP and Helix Transendocardial Delivery Catheter - AInvest
New Strong Sell Stocks for August 5th - The Globe and Mail
Biocardia Stock Plunges 12.76% Amid Market Volatility - AInvest
Biocardia, Inc. shares fall 12.76% premarket after providing update on regulatory approvals. - AInvest
Biocardia, Inc. shares fall 5.61% premarket after providing update on regulatory activities. - AInvest
What makes BioCardia Inc. stock price move sharplyLong-Term Safety Investment Analysis Report - Newser
BioCardia Faces Market Slump as Resale Registration Trigger Shares Drop - StocksToTrade
Biocardia, Inc. shares fall 14.51% intraday after providing update on regulatory activities. - AInvest
0.77%
3.10%
자본화:
|
볼륨(24시간):